Aura Biosciences Inc. (AURA)
Aura Biosciences Statistics
Share Statistics
Aura Biosciences has 50.27M shares outstanding. The number of shares has increased by 1.38% in one year.
| Shares Outstanding | 50.27M |
| Shares Change (YoY) | 1.38% |
| Shares Change (QoQ) | 0.55% |
| Owned by Institutions (%) | 79.43% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 7,768 |
| FTD / Avg. Volume | 2.94% |
Short Selling Information
The latest short interest is 1.95M, so 3.89% of the outstanding shares have been sold short.
| Short Interest | 1.95M |
| Short % of Shares Out | 3.89% |
| Short % of Float | 5.26% |
| Short Ratio (days to cover) | 5.86 |
Valuation Ratios
The PE ratio is -4.7 and the forward PE ratio is -2.62. Aura Biosciences's PEG ratio is 0.5.
| PE Ratio | -4.7 |
| Forward PE | -2.62 |
| PS Ratio | 0 |
| Forward PS | 1.6 |
| PB Ratio | 2.69 |
| P/FCF Ratio | -5.03 |
| PEG Ratio | 0.5 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aura Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.77, with a Debt / Equity ratio of 0.12.
| Current Ratio | 10.77 |
| Quick Ratio | 10.77 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | -0.22 |
| Debt / FCF | -0.23 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-819,990.57 |
| Employee Count | 106 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 112K |
| Effective Tax Rate | -0.13% |
Stock Price Statistics
The stock price has increased by -21.88% in the last 52 weeks. The beta is 0.43, so Aura Biosciences's price volatility has been higher than the market average.
| Beta | 0.43 |
| 52-Week Price Change | -21.88% |
| 50-Day Moving Average | 6.47 |
| 200-Day Moving Average | 8.25 |
| Relative Strength Index (RSI) | 53.99 |
| Average Volume (20 Days) | 264,380 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -96.12M |
| Net Income | -86.92M |
| EBITDA | -85.58M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.75 |
Balance Sheet
The company has 31.69M in cash and 18.77M in debt, giving a net cash position of 12.92M.
| Cash & Cash Equivalents | 31.69M |
| Total Debt | 18.77M |
| Net Cash | 12.92M |
| Retained Earnings | -374.23M |
| Total Assets | 182.5M |
| Working Capital | 145.71M |
Cash Flow
In the last 12 months, operating cash flow was -79.81M and capital expenditures -1.25M, giving a free cash flow of -81.06M.
| Operating Cash Flow | -79.81M |
| Capital Expenditures | -1.25M |
| Free Cash Flow | -81.06M |
| FCF Per Share | -1.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for AURA is $23.5, which is 287.1% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $23.5 |
| Price Target Difference | 287.1% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 1.66 |
| Piotroski F-Score | 1 |